```markdown
---
application_number: BLA 761312
application_type: Complete Response
applicant: Citius Pharmaceuticals, Inc.
product_name: Lymphir
proprietary_name: Lymphir (denileukin diftitox-cxdl)
submission_date: 2022-09-28
correspondence_contact:
  name: Catherine Kessler
  title: Executive VP, Regulatory Affairs
  address: 11 Commerce Dr., 1st Floor, Cranford, NJ 07016
fda_contact:
  name: Ashlee Bow
  title: Regulatory Project Manager
  phone: 301-796-6716
  email: ashlee.bow@fda.hhs.gov
signatory:
  name: Nicholas Richardson, DO, MPH
  title: Deputy Division Director (Acting)
  division: Division of Hematologic Malignancies II
  office: Office of Oncologic Diseases, Office of New Drugs, CDER
signature_date: 2023-07-28T11:20:32
proprietary_name_accepted: true
resubmission_required: true
facility_inspection_required: true
---

## Critical Data

- **Application Number**: BLA 761312  
- **Applicant**: Citius Pharmaceuticals, Inc.  
- **Proprietary Name**: Lymphir  
- **Nonproprietary Name**: denileukin diftitox-cxdl  
- **Submission Date**: September 28, 2022  
- **Complete Response Letter Issued**: July 28, 2023  
- **FDA Contact**: Ashlee Bow (ashlee.bow@fda.hhs.gov, 301-796-6716)  
- **Signatory**: Nicholas Richardson, DO, MPH  
- **Proprietary Name Acceptance**: Acceptable pending approval (as of 03/24/2023)  
- **Facility Inspection Needed**: Yes  
- **Resubmission Required**: Yes  
- **Next Steps**: Applicant must resubmit within one year or face application withdrawal under 21 CFR 601.3(c)  

---

# BLA 761312 â€“ COMPLETE RESPONSE

Citius Pharmaceuticals, Inc.  
**Attention**: Catherine Kessler  
Executive VP, Regulatory Affairs  
11 Commerce Dr., 1st Floor  
Cranford, NJ 07016  

---

Dear Ms. Kessler,

Please refer to your biologics license application (BLA) dated and received September 28, 2022, and your amendments, submitted under section 351(a) of the Public Health Service Act for **Lymphir (denileukin diftitox-cxdl) for injection**.

We also acknowledge receipt of your amendment dated July 26, 2023, which was not reviewed for this action. You may incorporate applicable sections of the amendment by specific reference as part of your response to the deficiencies cited in this letter.

We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. Below are the reasons for this action, with recommendations to address these issues where possible.

---

## PRODUCT QUALITY

1.  
   (b)(4)

> 2 page(s) have been withheld in full as (b)(4) (CCI/TS) immediately following this page.

---

## PRESCRIBING INFORMATION

Submit draft labeling that is responsive to our electronic communication dated July 14, 2023.

Before resubmitting the labeling:

- Use the SRPI checklist to correct any formatting errors to ensure conformance with the format items in regulations and guidances.
- Submit updated content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format as described at [FDA SPL Guide](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm).

To facilitate our review:

- Provide a highlighted or marked-up copy showing all changes.
- Include a clean Word version.
- The marked-up copy should include annotations supporting any proposed changes.

Your proposed Prescribing Information (PI) must conform to the content and format regulations found at 21 CFR 201.56(a), 201.56(d), and 201.57.  

We recommend reviewing the following labeling resources:

- [Prescription Drug Labeling Resources](https://www.fda.gov/drugs/laws-acts-and-rules/prescription-drug-labeling-resources)
- [Pregnancy and Lactation Labeling Final Rule](https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-drugs-final-rule)

These include:

- The Final Rule (Physician Labeling Rule) on content and format of the PI for human drug and biological products.
- The Final Rule (Pregnancy and Lactation Labeling Rule) for information on pregnancy, lactation, and females and males of reproductive potential.
- Regulations and related guidance documents.
- Sample tool illustrating format for Highlights and Contents.
- SRPI checklist for format items.
- FDAâ€™s established pharmacologic class (EPC) text phrases for Highlights Indications and Usage.
- Additional resources for PI, patient labeling, and carton/container labeling.

---

## CARTON AND CONTAINER LABELING

We reserve comment on the proposed labeling until the application is otherwise adequate.

---

## PROPRIETARY NAME

Please refer to correspondence dated March 24, 2023, addressing the proposed proprietary name, **Lymphir**. This name was found acceptable pending approval of the application in the current review cycle. Please resubmit the proposed proprietary name when you respond to this letter.

---

## FACILITY INSPECTIONS

An inspection of the (FEI #) facility is required before this application can be approved.

FDA must assess the ability of that facility to conduct listed manufacturing operations in compliance with CGMP. Due to the timing of incorporation of the site into the license application, we were unable to conduct an inspection during the current review cycle.

---

## SAFETY UPDATE

When responding to the above deficiencies, include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b). This should include data from all nonclinical and clinical studies/trials of the product under consideration regardless of indication, dosage form, or dose level.

Details to include:

1. Describe any significant changes or findings in the safety profile.
2. When providing data on discontinuations, serious adverse events, and common adverse events:
   - Present new safety data using the same format as the original submission.
   - Provide tabulations combining new and original application data.
   - Include tables comparing frequencies of events in original vs. updated data.
   - For other indications, provide separate tables of adverse event frequencies.
3. Retabulate reasons for premature trial discontinuation; describe any new trends or patterns.
4. Provide case report forms and narrative summaries for:
   - Each subject who died during a trial.
   - Subjects who did not complete due to an adverse event.
   - Serious adverse event descriptions.
5. Highlight any changes in incidence of common, but less serious, adverse events.
6. Update exposure information (e.g., number of subjects, person-time).
7. Provide a summary of global safety experience, including updated use estimates in other countries.
8. Submit English translations of current approved foreign labeling not previously submitted.

---

## ADDITIONAL COMMENTS

We have the following comments/recommendations that are not approvability issues:

1.  
   (b)(4)  
2.  
   (b)(4)  
3.  
   (b)(4)  

---

## OTHER

Within one year after the date of this letter, you are required to:

- Resubmit the application, or  
- Take other action under 21 CFR 601.3(b)

Failure to respond within this time may be considered a request to withdraw the application under 21 CFR 601.3(c). You may also request an extension to resubmit.

A resubmission must:

- Fully address all deficiencies listed in this letter
- Be clearly marked "RESUBMISSION" in large, bolded font on the cover letter
- Include a statement that the resubmission is a complete response to the deficiencies

A partial response will not be processed as a resubmission and will not start a new review cycle.

You may request a meeting or teleconference to discuss necessary steps before approval. Submit your meeting request in accordance with the draft guidance:  
**Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products**

The product may not be marketed until written approval is received.

---

## Contact Information

If you have any questions, contact:

**Ashlee Bow**  
Regulatory Project Manager  
ğŸ“ 301-796-6716  
ğŸ“§ ashlee.bow@fda.hhs.gov  

---

Sincerely,  
Nicholas Richardson, DO, MPH  
Deputy Division Director (Acting)  
Division of Hematologic Malignancies II  
Office of Oncologic Diseases  
Office of New Drugs  
Center for Drug Evaluation and Research  

---

> This is an electronic record signed electronically.  

**/s/**  
**Nicholas C. Richardson**  
ğŸ—“ï¸ 07/28/2023 11:20:32 AM  
```